SEC Form 4 · accession 0001179110-18-002586
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew J Greenfield
Officer — VP Healthcare Solutions
Period of report
Feb 20, 2018
Accepted (ET)
Feb 22, 2018 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par valueF5 | Feb 20, 2018 | M | 10,000 | $23.15 | A | 59,087 | D | |
| Common Stock, $.01 par valueF5 | Feb 20, 2018 | M | 5,000 | $14.39 | A | 64,087 | D | |
| Common Stock, $.01 par valueF5 | Feb 20, 2018 | M | 5,000 | $21.55 | A | 69,087 | D | |
| Common Stock, $.01 par valueF5,F6 | Feb 20, 2018 | S | 1,900 | $268.3205 | D | 67,187 | D | |
| Common Stock, $.01 par valueF5,F7 | Feb 20, 2018 | S | 4,727 | $269.4781 | D | 62,460 | D | |
| Common Stock, $.01 par valueF5,F8 | Feb 20, 2018 | S | 7,540 | $270.4537 | D | 54,920 | D | |
| Common Stock, $.01 par valueF5,F9 | Feb 20, 2018 | S | 3,933 | $271.283 | D | 50,987 | D | |
| Common Stock, $.01 par valueF5,F10 | Feb 20, 2018 | S | 1,800 | $272.3164 | D | 49,187 | D | |
| Common Stock, $.01 par valueF5 | Feb 20, 2018 | S | 100 | $273.04 | D | 49,087 | D | |
| Common Stock, $.01 par valueF11 | Feb 7, 2018 | G | 6,970 | $0.00 | D | 42,117 | D | |
| Common Stock, $.01 par valueF11 | Feb 20, 2018 | G | 6,970 | $0.00 | A | 6,970 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F5,F1 | $14.39 | Feb 20, 2018 | M | 5,000 | D | Feb 19, 2014 | Feb 19, 2023 | Common Stock | 5,000 | 0 | D |
| Stock Option (Right to Buy)F2,F5,F1 | $23.15 | Feb 20, 2018 | M | 10,000 | D | May 14, 2014 | May 14, 2023 | Common Stock | 10,000 | 0 | D |
| Stock Option (right to buy)F2,F5,F3 | $21.55 | Feb 20, 2018 | M | 5,000 | D | May 14, 2015 | May 14, 2024 | Common Stock | 15,000 | 10,000 | D |
| Stock Option (right to buy)F2,F3 | $66.25 | holding | — | — | — | May 13, 2016 | May 13, 2025 | Common Stock | 0 | 5,000 | D |
| Stock Option (right to buy)F4,F3 | $99.62 | holding | — | — | — | May 24, 2017 | May 24, 2026 | Common Stock | 0 | 5,000 | D |
| Stock Option (right to buy)F4,F3 | $134.51 | holding | — | — | — | May 15, 2018 | May 15, 2027 | Common Stock | 0 | 6,500 | D |
Explanation of responses
- F1These options became exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $272.0400 and $272.7100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F11This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust
- F2Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2008 Stock Incentive Plan.
- F3These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F4Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- F5Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F6This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $267.9000 and $268.8300. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $269.0100 and $269.7700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $269.9700 and $270.8700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $270.9100 and $271.7100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.